The more you read - the more this drug seems likely to be underwhelming…
“The agency rejected cariprazine in 2013 and demanded more clinical trial data to determine the ideal dose of the drug, its inventors said at the time. Two years later, Allergan and Gedeon completed a follow-up Phase III trial in which cariprazine met its goals of reducing schizophrenic relapses compared with placebo, adding those results to combined data from more than 2,700 schizophrenia and bipolar patients in their successful resubmission.”
Cariprazine, to be sold as Vraylar, was once considered a potential blockbuster, with Richter setting its sales potential at as much as $2 billion a year. But the drug’s long path to market has dampened enthusiasm among analysts, and Evercore-ISI’s Umer Raffat pegs its peak value closer to $200 million a year.
The drug is a potent dopamine D3/D2 receptor partial agonist atypical antipsychotic…
Nothing really new here - Abilify is in the same class of medications…
and